PROBLEMS OF PHARMACEUTICAL PROVISION OF POPULATION WITH HYPOLIPIDEMIC DRUGS: THE CASE OF THE VOLGOGRAD REGION (THE RUSSIAN FEDERATION)


Cite item

Full Text

Abstract

The aim of the study is to study the regional hypolipidemic drugs market, external and internal factors affecting their level of consumption, including the information awareness of the final customers about this pharmacotherapeutic group and the adherence to treatment with these drugs.

Materials and methods. The study was carried out using the methods of SWOT and STEP-analyses to assess the factors affecting the consumption of the studied group of drugs, as well as the questionnaire method of final customers and assessing their compliance using the Morisky-Green questionnaire.

Results. The influence of environmental and internal factors on the level and structure of the consumption of hypolipidemic drugs has been studied, hereby, the problems of the group and ways to solve them have been outlined, and an increase or decrease in the need for hypolipidemic drugs at the regional level, have been predicted. The assessment of the information awareness and preferences of the final customers of hypolipidemic drugs has been carried out, and insufficient awareness of patients about the drugs under study, has been revealed. The compliance of the final customers has been studied. A low level of the compliance of the patients to the prescribed hypolipidemic therapy has been established.

Conclusion. Modern advances in the treatment of cardiovascular diseases, based on fundamental achievements of science and practice, have created a high evidence base for the choice of strategies for pharmacotherapy with hypolipidemic drugs. The main ways to increase information awareness and compliance of the final customers are: development and intensification of educational programs to increase the level of knowledge and information awareness of doctors and pharmaceutical professionals, establishing the Doctor-Patient partnering relationships, increasing the trust level to the doctor and, as a result, the level of the patient compliance уровень; the development of materials for increasing the information awareness among the final customers about hypolipidemic drugs and hypolipidemic therapy in general.

About the authors

Ivan N. Tyurenkov

Volgograd State Medical University

Email: fibfuv@mail.ru
ORCID iD: 0000-0001-7574-3923

Doctor of Sciences (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences, Volgograd State Medical University, Head of the Laboratory of Pharmacology of Cardiovascular Means (Scientific Center of Innovative Medicine Remedies), Head of the Department of Pharmacology and Pharmacy (Institute of continuous – flow medical and pharmaceutical education).

Russian Federation, Volgograd

Julia S. Knyazeva

Volgograd State Medical University

Email: knjazeva1978@mail.ru
ORCID iD: 0000-0002-9571-2793

Candidate of Sciences (Pharmacy), Associate Professor, Department of Clinical Pharmacology and Intensive Care, Volgograd State Medical University.

Russian Federation, Volgograd

Lyudmila M. Ganicheva

Volgograd State Medical University

Email: Ganicheva@volgmed.ru
ORCID iD: 0000-0002-5647-0568

Doctor of Sciences (Pharmacy), Associate Professor, Head of the Department of Management and Economics of Pharmacy, Medical and Pharmaceutical Commodity Merchandising, Volgograd State Medical University.

Russian Federation, Volgograd

Nelli Sh. Kaysheva

Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University

Author for correspondence.
Email: caisheva2010@yandex.ru

Doctor of Sciences (Pharmacy), Professor of the Department of Pharmaceutical and Toxicological Chemistry, Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University.

Russian Federation, Pyatigorsk

References

  1. Aronov DM, Lupanov VP. Ateroskleroz i koronarnaya bolezn’ serdtsa [Atherosclerosis and coronary heart disease] M.: Triad – X. 2009. Russian
  2. Oganov RG, Maslennikova GYa. Demograficheskiye tendentsii v Rossiyskoy Federatsii: vklad bolezney sistemy krovoobrashcheniya [Demographic trends in the Russian Federation: the contribution of circulatory system diseases]. Cardiovascular Therapy and Prevention. 2012;11(1):5–10. Russian
  3. Bubnova MG. Klyuchevyye polozheniya novykh (2016 god) yevropeyskikh rekomendatsiy po upravleniyu dislipidemiyami i kommentariyami [Key provisions of the new (2016) European recommendations for the management of dyslipidemia and comments]. Medical Council. 2016; 19:12–20. Russian
  4. Yezhov MV, Sergienko IV, Aronov DM. Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel’yu profilaktiki i lecheniya ateroskleroza. Rossiyskiye rekomendatsii VI peresmotr [Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision]. The Journal of Atherosclerosis and Dyslipidemias. 2017;3:5–22. Russian
  5. Kulikov VA. Fremingemskoye issledovaniye serdtsa: 65 let izucheniya prichin ateroskleroza [Framingham heart study: 65 years of studying the causes of atherosclerosis]. Vestnik of Vitebsk State Medical University. 2012;11(2):16–24. Russian
  6. Fedorishina O. Dokazatel’naya baza rozuvastatina: mezhdunarodnyye i otechestvennyye issledovaniya [Evidence base of rosuvastatin: international and domestic research]. The Doctor. 2013;9:41–5. Russian
  7. Susekov AV, Khokhlova NV. Dokazatel’naya baza atorvastatina – pyatnadtsat’ let spustya [The evidence base of atorvastatin – fifteen years later]. Cardiovascular Therapy and Prevention. 2011;10(3):103–12. Russian
  8. Zadionchenko VS, Shekhyan GG, Alymov AA. Mesto statinov v terapii bol’nykh ishemicheskoy bolezn’yu serdtsa [The place of statins in the treatment of patients with coronary heart disease]. Russian Medical Journal. 2004;9:513–18. Russian
  9. Shalaev SV, Safiullina ZM, Kozlov AA. Statiny i ostryy koronarnyy sindrom: obosnovaniye, tselesoobraznost’ i taktika lecheniya patsiyentov [Statins and acute coronary syndrome: rationale, feasibility and tactics of treating patients]. Farmateka. 2013;18 (271):18–23. Russian
  10. Karpov YuA, Bulkina OS. Yevropeyskiye Rekomendatsii po lecheniyu dislipidemiy – 2016. Lipidsnizhayushchaya terapiya u patsiyentov s ostrym koronarnym sindromom i chreskozhnymi koronarnymi vmeshatel’stvami [European guidelines for the treatment of dyslipidemia – 2016. Lipid – lowering therapy in patients with acute coronary syndrome and percutaneous coronary interventions]. Medical Council. 2016;17:18–23. Russian
  11. Ozova EM Kiyakbaev GK, Kobalava ZhD. Statiny i khronicheskaya serdechnaya nedostatochnost’: rezul’taty issledovaniya CORONA [Statins and chronic heart failure: results of the CORONA study]. Сlinical Pharmacology and Therapy. 2008; 17(3):25–32. Russian
  12. Alexandrov AA, Yadrikhinskaya MN, Kukharenko SS, Shatskaya OA. Ctatiny i sakharnyy diabet: tsena sotrudnichestva [Statins and diabetes: the price of cooperation]. Diabetes mellitus. 2012;2:70–6. Russian
  13. Shilov AM, Melnik MV, Hosea AO. Mesto statinov v korrektsii narusheniy lipidnogo obmena u patsiyentov s metabolicheskim sindromom [The place of statins in the correction of lipid metabolism disorders in patients with metabolic syndrome]. Attending doctor. 2010;4:68–72. Russian
  14. Zagidullin NSh, Michels G. Statiny i ikh antiaritmicheskaya aktivnost’ [Statins and their antiarrhythmic activity]. Cardiovascular Therapy and Prevention. 2007;6(8):116–21. Russian
  15. Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides, Nucleotides & Nucleic Acids. 2010;29 (4 – 6):321–24.
  16. Nedomolkina SA, Velikaya OV, Batisheva GA, Velikii AV. Statiny u bol’nykh khronicheskoy obstruktivnoy bolezn’yu logkikh i sakharnym diabetom 2 tipa [Statins in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus]. System analysis and management in biomedical systems. 2017;16(2):248–53. Russian
  17. Smakotina SA, Zelendinova AR, Bondareva IN. Atorvastatin v preduprezhdenii serdechno – sosudistykh zabolevaniy u patsiyentov s revmatoidnym artritom [Atorvastatin in the prevention of cardiovascular disease in patients with rheumatoid arthritis]. Farmateka. 2017;9(342):44–9. Russian
  18. Grigoryeva IN, Nikitin YuP. Statiny i zhelchnokamennaya bolezn’ [Statins and gallstone disease]. Сlinical Pharmacology and Therapy. 2007;16(1):66–70. Russian
  19. Kashtalap VV, Khryachkova ON, Barbarash OL. Statiny i osteoporoz [Statins and osteoporosis]. Creative Cardiology. 2016;10(4):317–23. Russian
  20. Svistunov AA, Osadchuk MA, Kireeva NV. Perspektivy klinicheskogo primeneniya statinov v gastroenterologi [Prospects for the clinical use of statins in gastroenterology]. Clinical Medicine. 2016;94(3):172–77. Russian
  21. Ivanov DD. Ctatiny v nefrologii: Chto govoryat pol’zovateli? [Statins in Nephrology: What Do Leaders Say?]. Kidneys. 2013;4(06):19–20. Russian
  22. Mukhin IV. Vliyaniye dlitel’noy differentsirovannoy gipolipidemicheskoy terapii na lipidnyye i pleyotropnyye effekty, a takzhe chastotu dostizheniya konechnykh tochek u normotenzivnykh bol’nykh khronicheskim glomerulonefritom [The effect of prolonged differentiated hypolipidemic therapy on lipid and pleiotropic effects, as well as the frequency of reaching endpoints in normotensive patients with chronic glomerulonephritis]. Nephrology. 2006;10(3):43–7. Russian
  23. Drapkina OM, Avilova AG. Statiny i nealkogol’naya zhirovaya bolezn’ pecheni [Statins and non – alcoholic fatty liver disease]. The Journal of Atherosclerosis and Dyslipidemias. 2014;1:31–5. Russian
  24. Alekperov RT, Lyubimova EG. Ctatiny pri sistemnoy sklerodermii [Statins in systemic scleroderma]. Medical Council. 2008;5 – 6:57–60. Russian
  25. Knyazeva YuS, Tyurenkov IN. Rynok gipolipidemicheskikh sredstv: klinicheskaya effektivnost’, kriterii bezopasnosti i perspektivy primeneniya novykh lekarstvennykh preparatov dlya lecheniya dislipidemiy [The market of lipid – lowering drugs: clinical efficacy, safety criteria and prospects for the use of new drugs for the treatment of dyslipidemia]. Remedium. 2016;9:28–34. Russian
  26. Knyazeva YuS. Struktura potrebleniya gipolipidemicheskikh lekarstvennykh preparatov v roznichnom segmente farmatsevticheskogo rynka Volgogradskoy oblasti [The structure of the consumption of lipid – lowering drugs in the retail segment of the pharmaceutical market of the Volgograd region]. Medical almanac. 2017;6(51):158–62. Russian
  27. Zykov MV, Berns SA, Kastalap VV, Barbarash OL. Priverzhennost’ k gipolipidemicheskoy terapii v techeniye 3kh let posle OKS [Adherence to lipid – lowering therapy for 3 years after ACS]. The Journal of Atherosclerosis and Dyslipidemias. 2017;2:58–67. Russian
  28. Lukina YuV, Polyanskaya YuN, Tolpygina SN, Ajdu FA, Marcevich SYu, Voronina VP, Gofman EA, Dmitrieva NA, Deev AD, Lerman OV, Malysheva AM, Medvedkov DI, Neplyuhin SM, Heliya TG. Izucheniye priverzhennosti lecheniyu patsiyentov s khronicheskoy i ishemicheskoy bolezn’yu serdtsa i sootvetstviyu trebovaniyam gipolipidemicheskoy terapii klinicheskim rekomendatsiyam (po dannym registratsii PROGNOZ IBS) [A study of adherence to statin treatment in patients with chronic coronary heart disease and the correspondence of lipid – lowering therapy to clinical recommendations (according to the IHD FORECAST register)]. Russian Journal of Preventive Medicine and Public Health. 2014;17(4):39–43. Russian
  29. Okhremenko IV, Burov AN, Dilman DA. Demograficheskoye stareniye: istoriko – sotsiologicheskiy aspekt (na primere g. Volgograda i Volgogradskoy oblasti) [Demographic aging: historical and sociological aspect (for example, the city of Volgograd and the Volgograd region)]. Modern problems of science and education. 2015;1(1):1510. Russian
  30. Mishchenko MA, Kononova SV. Analiz faktorov, vliyayushchikh na priverzhennost’ k gipolipidemicheskoy terapii [Analysis of factors affecting adherence to lipid – lowering therapy]. Medical almanac. 2014;1(31):95–8. Russian
  31. Analiz smertnosti ot bolezney sistemy krovoobrashcheniya na territorii Volgogradskoy oblasti. Faktory riska i profilaktika zabolevaniy sistemy krovoobrashcheniya [Analysis of mortality from diseases of the circulatory system in the Volgograd region. Risk factors and prevention of circulatory system diseases]. [cited 2019 Oct 17]. Available from: http://34.rospotrebnadzor.ru/upload/iblock/ced/081117_Analysis of mortality from diseases of the circulatory system.pdf () Russian
  32. Knyazeva YuS. Otsenka informirovannosti farmatsevticheskikh spetsialistov Volgogradskogo regiona o farmakoterapii gipolipidemicheskimi preparatami [Awareness assessment of pharmaceutical specialists of the Volgograd region about pharmacotherapy with lipid – lowering drugs]. Actual problems of experimental and clinical medicine: Materials of the 74th open scientific – practical conference of young scientists and students of Volgograd State Medical University with international participation. 2016. 427 p. Russian

Copyright (c) 2020 Tyurenkov I.N., Knyazeva Y.S., Ganicheva L.M., Kaysheva N.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies